Mineralocorticoids (aldosterone)

Aldosterone is the main human mineralocorticoid and represents the most important endocrine signal for the fine regulation of sodium-potassium balance and, consequently, extracellular volume and blood pressure. Its function is not limited to controlling renal sodium reabsorption. Aldosterone acts as a regulator of electrolyte homeostasis and as a modulator of cellular programs involving ion transport, tissue remodeling and responses to hemodynamic stress. Mineralocorticoid signaling is therefore an example of precision endocrinology, because it integrates subtle variations in renal perfusion, sodium balance, plasma potassium concentration and sympathetic tone into a hormonal output that must be rapid, appropriate and selective for specific tissues.

Aldosterone physiology also provides a model of integration between molecular biology and organ physiology. Adrenocortical biosynthesis depends on a steroidogenic cascade that begins with cholesterol and culminates in the activity of aldosterone synthase, an enzyme expressed with high selectivity in the zona glomerulosa. Regulation is dominated by the renin-angiotensin system, potassium and local paracrine signals rather than by adrenocorticotropic hormone (ACTH), which mainly has a permissive or transient role. Biological action occurs through the mineralocorticoid receptor, with genomic effects on channels and transporters, but also includes rapid responses and interactions with signaling pathways. This page examines aldosterone throughout its entire functional pathway, from steroidogenesis to tissue-specific regulation of its action and the interpretative limitations of plasma values alone.

The mineralocorticoid system is designed to ensure stable control of extracellular volume and plasma potassium concentration despite wide fluctuations in salt intake and hemodynamic requirements. The main physiological target is the kidney, where aldosterone increases sodium reabsorption and potassium secretion, stabilizing volume and the transmembrane electrical potential in the distal nephron. Aldosterone, however, is not exclusively a renal hormone. The mineralocorticoid receptor is also expressed in the endothelium, vascular smooth muscle, heart, adipose tissue and specific neuronal populations, where its effects contribute to the integration of blood pressure regulation, local inflammatory responses and tissue remodeling.

A fundamental aspect of mineralocorticoid signaling is the need to achieve specificity in a context in which the mineralocorticoid receptor also binds glucocorticoids with high affinity. In classical aldosterone-sensitive tissues, such as the kidney and colon, specificity is protected by the prereceptor inactivation of cortisol through 11β-HSD2. This allows aldosterone, despite being present at lower concentrations than cortisol, to function as the effective receptor ligand. Mineralocorticoid physiology therefore depends not only on the hormone itself but also on mechanisms that prevent cortisol from occupying the receptor in tissues where this would be biologically inappropriate.

In addition to receptor control, specificity also emerges from the mechanisms regulating aldosterone secretion. Hormonal output is driven primarily by renal sensing of perfusion and sodium delivery, as well as by plasma potassium concentration, creating a feedback circuit that directly links hemodynamic and electrolyte status to hormone secretion. This circuit, centered on the renin-angiotensin system, is one of the clearest examples of endocrine regulation in which a hormonal signal represents the final result of an information pathway that begins with peripheral sensors and culminates in a zonally organized adrenal enzymatic program.

Three principles explain how aldosterone maintains fluid-electrolyte homeostasis while preserving signal specificity:

• renin-angiotensin-driven regulation, which converts information about perfusion and sodium delivery into direct stimulation of the zona glomerulosa;
• potassium sensing, which rapidly links plasma potassium concentration to mineralocorticoid output in order to protect neuromuscular and cardiac excitability;
• prereceptor control through 11β-HSD2 in target tissues, which prevents cortisol from occupying the mineralocorticoid receptor.

This architecture makes aldosterone biosynthesis the natural starting point. Mineralocorticoid production is a specific enzymatic program of the zona glomerulosa, with steps shared by other steroidogenic pathways but a distinctive final segment that determines the identity and regulation of the signal.

Aldosterone synthesis occurs in the zona glomerulosa of the adrenal cortex and shares the initial stages of steroidogenesis with other adrenal steroids. The first quantitative control point is the availability of cholesterol within the mitochondrion, regulated by the steroidogenic acute regulatory protein (StAR), which facilitates transport of the substrate to the inner mitochondrial membrane. Here, CYP11A1 converts cholesterol into pregnenolone, initiating the cascade. This step is shared by several steroidogenic pathways and illustrates how the adrenal gland uses a common biosynthetic platform that is subsequently differentiated according to the adrenal zone and the enzymes expressed.

In the zona glomerulosa, the pathway continues through the formation of progesterone and subsequently deoxycorticosterone through CYP21A2. The distinctive feature is the presence of aldosterone synthase, also known as CYP11B2, a mitochondrial enzyme capable of catalyzing oxidative reactions that lead to the formation of aldosterone from mineralocorticoid precursors. Zonal selectivity results from the expression of CYP11B2 in the zona glomerulosa, whereas the zona fasciculata predominantly expresses CYP11B1, directing hormonal output toward aldosterone and cortisol, respectively.

Aldosterone production also requires a cellular environment in which ionic signals and second messengers regulate enzymatic activity and gene expression. In the zona glomerulosa, membrane depolarization and increased intracellular calcium are key drivers that connect stimuli such as potassium and angiotensin II to a biosynthetic response. This highlights a general principle: while the production of other adrenal steroids is dominated by cyclic adenosine monophosphate-dependent signaling, aldosterone secretion is strongly dependent on calcium-mediated control, allowing rapid adaptation to electrolyte changes.

Mineralocorticoid biosynthesis must therefore be understood as a zonal program built upon a shared platform but rendered specific by CYP11B2 expression and by regulation that favors membrane and calcium-mediated signals. This provides the basis for understanding physiological regulation, which is dominated by the renin-angiotensin system and potassium and converts the biosynthetic capacity of the zona glomerulosa into hormonal output consistent with hemodynamic and electrolyte requirements.

Aldosterone regulation is centered on the renin-angiotensin system. Reduced renal perfusion, decreased sodium chloride delivery to the macula densa and sympathetic adrenergic activation promote the release of renin from juxtaglomerular cells. Renin initiates the generation of angiotensin II, which acts on the zona glomerulosa through specific receptors and induces intracellular signaling that increases calcium and promotes both acute steroidogenesis and transcriptional remodeling of steroidogenic enzymes, particularly CYP11B2. In practical terms, angiotensin II converts the information of reduced effective circulating volume into increased mineralocorticoid output.

Plasma potassium is the second major determinant. An increase in plasma potassium concentration depolarizes glomerulosa cells and increases calcium influx, enhancing aldosterone production within a short time. This circuit directly links mineralocorticoid secretion to the protection of neuromuscular and cardiac excitability, because correction of plasma potassium concentration is an urgent physiological objective. From an integrated perspective, the renin-angiotensin system and potassium converge on intracellular calcium as a common activation pathway, making the response sensitive to both hemodynamic status and electrolyte balance.

Adrenocorticotropic hormone (ACTH) contributes differently from its role in cortisol regulation. It can transiently increase aldosterone production, particularly during acute stimulation, but it is not the dominant regulator of mineralocorticoid output under basal conditions. Its role can be regarded as permissive or modulatory, supporting the integrity of the shared steroidogenic machinery but remaining insufficient to govern aldosterone secretion without renal and potassium-mediated information. Local paracrine and autocrine signals produced within the adrenal gland also help define the sensitivity of the zona glomerulosa by integrating responses to systemic stimuli.

This regulatory architecture explains why aldosterone is closely linked to the kidney. The next step is to examine how the hormone travels in plasma and how the free fraction and mechanisms of cellular access contribute to its bioavailability in target tissues.

In plasma, aldosterone circulates partly bound to proteins, particularly albumin and, to a lesser extent, steroid-binding proteins. Compared with cortisol, its binding is less dependent on a single specific globulin, resulting in a relatively larger free fraction and more rapid pharmacokinetics. This characteristic is consistent with the physiological role of aldosterone, which must respond relatively quickly to variations in effective circulating volume and plasma potassium concentration by flexibly modulating distal nephron activity.

Tissue bioavailability depends on the free fraction and on the hormone’s ability to reach target tissues. The kidney receives a substantial proportion of cardiac output and therefore allows efficient delivery of aldosterone to distal nephron segments, where the hormone exerts its main effects on channels and pumps. Non-classical tissues can also be significantly exposed, and the biological impact in these tissues depends on receptor density, the inflammatory environment and the prereceptor mechanisms that protect mineralocorticoid receptor specificity.

Plasma transport alone does not explain signal selectivity. The critical point is how the mineralocorticoid receptor is protected from cortisol occupancy in tissues where aldosterone must be the dominant signal. This protection depends on prereceptor conversion mediated by 11β-HSD2, which is a cornerstone of mineralocorticoid physiology and an essential interpretative element for understanding many biological consequences of the system.

The mineralocorticoid receptor has high affinity for both aldosterone and cortisol. Because cortisol is present at much higher plasma concentrations, the receptor would predominantly be occupied by the glucocorticoid in the absence of a protective mechanism. In classical mineralocorticoid target tissues, particularly the kidney at the level of the distal tubule and collecting duct, the enzyme 11β-HSD2 inactivates cortisol by converting it into cortisone, markedly reducing the glucocorticoid’s ability to stimulate the receptor. Aldosterone can therefore function as the effective ligand, preserving the physiological specificity of the axis.

The same principle applies to the colon and salivary glands and has particular importance in the placenta, where protection from maternal cortisol helps regulate fetal glucocorticoid exposure. Mineralocorticoid physiology therefore uses a prereceptor selection mechanism that concerns not only aldosterone but also the overall architecture of steroid receptors and their interactions with endogenous ligands.

Specificity is not merely a molecular detail but a functional mechanism that allows aldosterone to selectively control sodium and potassium homeostasis. This selectivity provides the basis for its action in the distal nephron, where aldosterone induces a coordinated electrolyte transport program involving channels, pumps and regulatory proteins, with measurable effects on volume and plasma potassium concentration.

In the kidney, aldosterone acts primarily on principal cells of the collecting duct and distal tubule, promoting sodium reabsorption and potassium secretion. The central effect is increased activity of the epithelial sodium channel (ENaC) on the apical membrane, which increases sodium entry into the cell. In parallel, aldosterone increases the activity of the basolateral Na/K-ATPase, which extrudes sodium into the interstitial compartment and transports potassium into the cell, maintaining the gradient required for continuous sodium movement through ENaC.

Increased sodium reabsorption makes the tubular lumen more electrically negative and facilitates potassium secretion through apical channels such as ROMK. It also modifies conditions affecting proton secretion by intercalated cells, establishing physiological connections between mineralocorticoid signaling and acid-base balance. The overall effect is an increase in sodium content within the extracellular compartment, with secondary water retention and expansion of effective circulating volume, together with protection against hyperkalemia through increased potassium excretion.

A central feature is that aldosterone action is intrinsically modulated by tubular flow, sodium delivery to the distal nephron and the functional state of the renin-angiotensin system. When distal sodium delivery is reduced, the effects of aldosterone may be limited, whereas increased sodium delivery can produce marked hormonal responses. This property emphasizes that aldosterone acts within an integrated circuit of renal physiology rather than as an isolated signal, and that its final effect results from the interaction between hormonal stimulation and the context of filtration and transport throughout the nephron.

Understanding these effects requires examination of the mineralocorticoid receptor and the genomic mechanisms that coordinate increases in channels, pumps and regulatory proteins. The transcriptional program forms the basis of the sustained effects of aldosterone, while rapid pathways complete adaptation over shorter timescales.

The classical action of aldosterone is genomic and mediated by the mineralocorticoid receptor (MR), a nuclear receptor that, after binding the hormone, translocates to the nucleus and regulates the expression of target genes. In renal tissues, MR activation induces a transcriptional program that increases the quantity and activity of key components of ion transport. A central element is the induction of serum and glucocorticoid-regulated kinase 1 (SGK1), which increases ENaC availability on the apical membrane by reducing its endocytosis and promoting functional stability. Transcriptional regulation is thereby converted into an effective increase in transcellular sodium transport.

The genomic program also involves proteins that regulate channel degradation and ubiquitination, factors controlling transporter density and Na/K-ATPase efficiency. The result is a sustained increase in sodium reabsorption, consistent with the long-term role of aldosterone in maintaining extracellular volume. The genomic response requires several hours because it depends on transcription, protein synthesis and membrane insertion of newly produced proteins. It therefore explains why aldosterone is particularly effective in persistently remodeling the transport state of the distal nephron.

The tissue specificity of aldosterone action depends on the presence of the MR, the context of coregulatory proteins and, particularly in classical target tissues, prereceptor protection. In non-epithelial tissues, the presence of the MR and the absence or reduced expression of 11β-HSD2 make signal interpretation more complex because cortisol can contribute to receptor occupancy. This concept is essential for understanding why extrarenal MR effects may be influenced not only by aldosterone but also by glucocorticoid status, local metabolism and inflammation.

Alongside genomic pathways, more rapid actions attributed to the MR and to membrane-associated interactions can modulate ion transport and cellular signaling over shorter periods. These pathways do not replace the transcriptional program but complement it, allowing more immediate adaptation to electrolyte and hemodynamic changes.

Aldosterone can induce rapid non-genomic responses involving cytoplasmic signaling pathways and immediate modulation of transporters and channels. In certain cellular contexts, MR activation can interact with kinases and second messengers that rapidly alter the function of ion transport components, contributing to more immediate regulation of sodium reabsorption. These effects are particularly relevant when the body must rapidly correct changes in plasma potassium concentration or effective circulating volume before gene transcription consolidates the adaptation.

At the vascular level, mineralocorticoid signaling can modulate tone and reactivity, particularly through interactions with angiotensin II and the local redox state. The interaction between aldosterone and angiotensin II is physiologically important because both signals converge in the regulation of blood pressure and renal perfusion. During chronic activation of the renin-angiotensin system, mineralocorticoid exposure can promote functional and structural changes in blood vessels and myocardium, with implications for vascular stiffness and remodeling. These concepts connect normal physiology with the risk of maladaptive effects when the system remains persistently overactive.

Overall, the existence of non-genomic pathways broadens the understanding of mineralocorticoid signaling without altering its central principle: the final biological effect depends on the combination of regulatory output, prereceptor protection, MR activation and tissue context. This synthesis leads to the final integrated framework combining biosynthesis, regulation, action and the interpretative limitations of biochemical parameters, explaining why aldosterone must be understood as part of a physiological circuit rather than as an isolated value.

Aldosterone physiology demonstrates that mineralocorticoid signaling results from an integrated sequence: zonal biosynthesis driven by CYP11B2, dominant regulation by the renin-angiotensin system and potassium, plasma transport with a functionally active free fraction, prereceptor selection in target tissues through 11β-HSD2 and, finally, genomic and non-genomic receptor responses that remodel ion transport and cardiovascular function. Each step can be modified by sodium balance, hemodynamic status, renal function and sympathetic activation, making aldosterone a highly context-dependent signal.

Plasma aldosterone measurement, when considered in isolation, does not automatically describe the mineralocorticoid status of the body. Hormonal output must be interpreted together with renin dynamics, effective circulating volume, plasma potassium concentration and the pharmacological context, which may modify the renin-angiotensin system. Tissue specificity also depends on the presence of 11β-HSD2 in epithelial tissues, whereas MR occupancy in other tissues may be influenced by glucocorticoids and local metabolism. Endocrinological interpretation therefore requires an integrated approach in which hormonal values, renal physiology and the systemic context are assessed as a single network.

In conclusion, aldosterone is an endocrine signal that preserves electrolyte homeostasis and hemodynamic stability through finely regulated secretion and receptor action that is strongly dependent on tissue context. Zonal biosynthesis and regulation by the renin-angiotensin system and potassium ensure appropriate hormonal output, while prereceptor selection preserves receptor specificity in target tissues. Genomic action accounts for sustained effects on ion transport, while non-genomic pathways complete adaptation through more rapid responses and integration with vascular signals. This framework is essential for understanding both the physiology of sodium balance and the conditions in which the mineralocorticoid axis becomes maladaptive.